Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report

Anti-Cancer Drugs · Published 2026-06-16 · DOI 10.1097/cad.0000000000001833

Authors (3)

Onur Alkan, Ahmet Başgöze, İsmail Nazli

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Alkan, O., Başgöze, A., Nazli, İ. (2026). Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000001833

Related articles

• Temozolomide-based therapy may remodel the tumor microenvironment and enhance immunotherapy sensitivity in advanced leiomyosarcoma · Anti-Cancer Drugs · 2026 · Same journal
• Activation of the caspase-1/gasdermin D pathway via α-linolenic acid-mediated GPR120 signaling induces pyroptosis and suppresses ovarian cancer tumor growth · Anti-Cancer Drugs · 2025 · Same journal
• Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S · Anti-Cancer Drugs · 2026 · Same journal
• Treatment of HRD-positive elderly ovarian cancer patient: a case report · Anti-Cancer Drugs · 2025 · Same journal
• Prochlorperazine inhibits the proliferation of hepatocellular carcinoma cells by promoting phosphorylation of β-catenin · Anti-Cancer Drugs · 2026 · Same journal
• Successful treatment with erlotinib plus ramucirumab in a patient with non-small-cell lung cancer harboring EGFR exon 20 insertion mutation · Anti-Cancer Drugs · 2025 · Same journal
• Dual checkpoint inhibition achieves successful treatment of diffuse bilateral lung metastasis in giant advanced liver cancer: a case report · Anti-Cancer Drugs · 2026 · Same journal
• Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen · Anti-Cancer Drugs · 2026 · Same journal
• SENP3-mediated deSUMOylation stabilizes programmed death-ligand 1 to promote immune evasion in hepatocellular carcinoma · Anti-Cancer Drugs · 2026 · Same journal
• Histone lactylation promoted colorectal cancer progression by enhancing tumor necrosis factor transcription and served as a diagnostic biomarker · Anti-Cancer Drugs · 2025 · Same journal